Literature DB >> 10574582

Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs.

H J Girschick1, H W Seyberth, H I Huppertz.   

Abstract

Hypophosphatasia (HP) is an inborn error of metabolism that is characterized by reduced bone mineralization. The aim of this investigation was to evaluate treatment of incapacitating lower limb pain in patients with childhood HP using nonsteroidal antiinflammatory drugs (NSAID). All patients (seven boys; age 32 months to 16 years) presented with delayed walking, the typical waddling gait, muscular weakness of the lower limbs, and a limited walking distance. Six patients had severe diffuse lower limb pain following physical activity and were therefore treated with NSAID. The benefit of this treatment was evaluated clinically and by measurement of renally (PGE2) and systemically (PGE-M) derived prostaglandins (PG) in urine before and during therapy. After treatment with NSAID all six patients showed marked clinical improvement with reduced pain, increased muscle strength, and a normalized walking distance. Levels of PGE-M, which had been elevated in four patients prior to therapy, returned to normal. The use of NSAID in childhood HP should be considered as a possible therapeutic approach because the quality of life in these patients is markedly impaired by pain of the limbs. Elevated PG might play a role in the bone metabolism of HP patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574582     DOI: 10.1016/s8756-3282(99)00203-3

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

Review 1.  Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.

Authors:  Christopher Eccleston; Tess E Cooper; Emma Fisher; Brian Anderson; Nick Mr Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

2.  Clinical utility gene card for: hypophosphatasia.

Authors:  Etienne Mornet; Christine Beck; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2010-10-27       Impact factor: 4.246

3.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

4.  Whole-body MRI in the childhood form of hypophosphatasia.

Authors:  C Beck; H Morbach; C Wirth; M Beer; H J Girschick
Journal:  Rheumatol Int       Date:  2010-04-10       Impact factor: 2.631

Review 5.  How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases?

Authors:  C Beck; H Morbach; P Richl; M Stenzel; H J Girschick
Journal:  Rheumatol Int       Date:  2008-09-28       Impact factor: 2.631

6.  Tissue-nonspecific alkaline phosphatase is an anti-inflammatory nucleotidase.

Authors:  L Bessueille; A Briolay; J Como; S Mebarek; C Mansouri; M Gleizes; A El Jamal; R Buchet; C Dumontet; E L Matera; E Mornet; J L Millan; C Fonta; D Magne
Journal:  Bone       Date:  2020-02-04       Impact factor: 4.398

Review 7.  Hypophosphatasia.

Authors:  Etienne Mornet
Journal:  Orphanet J Rare Dis       Date:  2007-10-04       Impact factor: 4.123

8.  Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia.

Authors:  H J Girschick; P Schneider; I Haubitz; O Hiort; H Collmann; M Beer; Y S Shin; H W Seyberth
Journal:  Orphanet J Rare Dis       Date:  2006-06-28       Impact factor: 4.123

9.  Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy.

Authors:  Hermann J Girschick; Etienne Mornet; Meinrad Beer; Monika Warmuth-Metz; Peter Schneider
Journal:  BMC Pediatr       Date:  2007-01-23       Impact factor: 2.125

Review 10.  Multiple Functions of MSCA-1/TNAP in Adult Mesenchymal Progenitor/Stromal Cells.

Authors:  David Estève; Jean Galitzky; Anne Bouloumié; Caroline Fonta; René Buchet; David Magne
Journal:  Stem Cells Int       Date:  2015-12-29       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.